NATRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NATURES SUNSHINE PRODUCTS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.55−0.09 (-0.71%)
Close on Oct 19, 2026
- Market cap
- $230.13M
- P/E (TTM)
- 12.4
- Dividend yield
- –
NATURES SUNSHINE PRODUCTS INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia | $53.00M | $52.18M | $55.74M | $64.73M | $52.66M | $48.65M | $56.30M | $55.29M | $49.98M | $46.22M | $47.81M | $52.22M | 45.3% | +0.6% |
| North America | $35.95M | $38.32M | $37.39M | $36.22M | $34.98M | $35.02M | $35.13M | $33.63M | $33.56M | $36.53M | $35.71M | $34.79M | 30.7% | +2.8% |
| Europe | $22.69M | $26.40M | $25.17M | $22.11M | $21.74M | $24.11M | $21.32M | $19.62M | $21.60M | $22.30M | $19.69M | $18.77M | 19.4% | +4.4% |
| Latin America and Other | $5.34M | $5.99M | $5.51M | $5.28M | $5.37M | $5.46M | $5.45M | $6.08M | $5.40M | $5.95M | $5.73M | $5.42M | 4.6% | -0.5% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia | $8.34M | $10.49M | $8.41M | $13.12M | $10.29M | $8.35M | $8.55M | $10.35M | $8.39M | $6.82M | – | – | -19.0% |
| North America | $7.92M | $9.12M | $8.94M | $7.79M | $6.39M | $7.74M | $7.36M | $7.44M | $7.78M | $8.34M | – | – | +23.9% |
| Europe | $2.10M | $2.77M | $1.82M | $2.32M | $1.74M | $2.17M | $1.35M | $706.00K | $828.00K | $1.78M | – | – | +20.3% |
| Latin America and Other | $403.00K | $723.00K | $205.00K | $275.00K | $361.00K | $387.00K | $494.00K | $691.00K | -$168.00K | $276.00K | – | – | +11.6% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General health | $48.90M | $49.07M | $46.94M | $51.89M | $47.38M | $45.92M | $46.07M | $48.78M | $45.26M | $43.77M | – | – | 41.8% | +3.2% |
| Digestive | $28.71M | $32.50M | $37.56M | $31.37M | $27.91M | $27.53M | $34.62M | $26.01M | $24.70M | $26.42M | – | – | 24.5% | +2.9% |
| Cardiovascular | $19.83M | $20.34M | $18.70M | $22.97M | $19.46M | $20.51M | $19.13M | $21.63M | $20.08M | $20.86M | – | – | 17.0% | +1.9% |
| Immunity | $8.73M | $10.15M | $9.72M | $10.74M | $10.09M | $10.28M | $12.48M | $8.47M | $8.59M | $9.19M | – | – | 7.5% | -13.4% |
| Personal care | $6.76M | $6.98M | $7.57M | $5.85M | $5.31M | $4.55M | $5.60M | $3.76M | $4.04M | $4.41M | – | – | 5.8% | +27.4% |
| Weight management | $4.06M | $3.86M | $3.33M | $5.54M | $4.61M | $4.46M | $307.00K | $5.97M | $7.89M | $6.35M | – | – | 3.5% | -12.0% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | $39.44M | $47.59M | – | $42.86M | $39.81M | $41.10M | – | $38.07M | $40.15M | – | – | – | 33.7% | -0.9% |
| United States | $33.57M | $35.64M | $34.70M | $33.72M | $32.49M | $32.47M | $32.32M | $30.97M | $30.95M | $33.69M | $32.99M | $32.24M | 28.7% | +3.3% |
| Japan | $18.23M | $12.45M | $14.16M | $17.70M | $13.18M | $11.03M | $11.80M | $13.29M | $9.69M | – | – | – | 15.6% | +38.3% |
| Taiwan | $13.73M | $14.99M | $13.83M | $18.85M | $16.73M | $17.86M | $20.09M | $18.39M | $16.31M | $15.79M | $15.88M | $15.60M | 11.7% | -17.9% |
| South Korea | $12.02M | $12.23M | $12.33M | $15.20M | $12.54M | $10.78M | $12.40M | $13.89M | $13.45M | $11.62M | $10.85M | $13.92M | 10.3% | -4.1% |
| Other | – | – | – | – | – | – | $9.46M | $51.36M | $49.85M | $49.89M | $49.22M | $49.44M | – | – |
| Other | – | – | – | – | – | $52.13M | – | – | – | $49.89M | – | – | – | – |
From the segment and revenue-disaggregation notes of Natures Sunshine Products's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.